— Know what they know.
Not Investment Advice

BEAM NASDAQ

Beam Therapeutics Inc.
1W: -6.3% 1M: -12.7% 3M: +0.3% YTD: +1.9% 1Y: +55.9% 3Y: -18.3% 5Y: -61.5%
$28.64
+0.97 (+3.51%)
 
Weekly Expected Move ±11.5%
$21 $25 $28 $31 $34
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 37 · $2.9B mcap · 94M float · 2.29% daily turnover · Short 67% of daily vol

Cash Flow Trends

Operating Cash Flow
-$345M +0.6% ▲
Capital Expenditures
$15M -67.1% ▼
5Y CAGR: -1.8%
Free Cash Flow
-$360M -1.1% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$12M +107.4% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$371M-$289M-$133M-$377M-$80M
Depreciation & Amort.$7M$14M$20M$22M$22M
Stock-Based Comp.$44M$84M$99M$121M$94M
Change in Working Capital$111M$252M-$116M-$110M-$131M
Other Non-Cash Items$142M-$38M-$19M-$3M-$251M
Operating Cash Flow-$66M$23M-$149M-$347M-$345M
— Investing Activities —
Capital Expenditures-$47M-$49M-$34M-$9M-$15M
Acquisitions (Net)$620K$412M$0$0-$78K
Investment Purchases-$777M-$1.6B-$984M-$486M-$1.2B
Investment Sales$529M$1.2B$1.1B$680M$849M
Other Investing$0-$412M$0$0$255M
Investing Cash Flow-$294M-$461M$72M$185M-$121M
— Financing Activities —
Net Debt Issuance-$2M-$2M-$2M-$485K$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$810K$6M$9M$0$0
Financing Cash Flow$756M$112M$276M$8M$478M
Net Change in Cash$396M-$327M$199M-$155M$12M
Cash End of Period$573M$246M$445M$290M$302M
Free Cash Flow-$113M-$26M-$183M-$356M-$360M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms